Hypodermoclysis for frail patients and patients in long term care a review of clinical effectiveness, cost effectiveness, and guidelines
Hypodermoclysis (HDC) is a method of administering fluids or medication subcutaneously (under the skin), as opposed to intravenously (IV; into a vein) or intramuscularly (into a muscle). Benefits of subcutaneous administration of medication include lower pain (as there are fewer pain receptors), goo...
| Main Authors: | , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa
Canadian Agency for Drugs and Technologies in Health
August 31, 2020, 2020
|
| Edition: | Version 1.0 |
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Hypodermoclysis (HDC) is a method of administering fluids or medication subcutaneously (under the skin), as opposed to intravenously (IV; into a vein) or intramuscularly (into a muscle). Benefits of subcutaneous administration of medication include lower pain (as there are fewer pain receptors), good irrigation, and lower proteolytic activity. However, HDC can be a costly procedure, and its effectiveness is debated, with a lack of literature or evidence for effectiveness, especially in specific populations. Therefore, the purpose of this report is to examine the clinical and cost effectiveness of HDC in frail patients or patients residing in long term care, as well as evidence-based guidelines regarding the use of HDC in these patients |
|---|---|
| Physical Description: | 1 PDF file (21 pages) |